Emerging topics in human tumor virology

International Journal of Cancer

Volumn 129, Issue 6, 2011, Pages 1289-1299

  Hoppe Seyler, Felix ^a   Hoppe Seyler, Karin ^a  

^a Program Infection and Cancer   (Germany)

Author keywords

cervical cancer; EBV; epigenetics; HBV; HCV; HIV; HPV; HTLV 1; liver cancer; miRNA; tumor viruses; vaccination; virus detection

Indexed keywords

DOUBLE STRANDED DNA; HEPATITIS B VACCINE; HERPES VACCINE; SINGLE STRANDED RNA; UNTRANSLATED RNA; WART VIRUS VACCINE;

ARTICLE; BURKITT LYMPHOMA; CANCER IMMUNIZATION; CANCER RISK; DNA TUMOR VIRUS; EPIGENETICS; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS; KAPOSI SARCOMA; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; NASOPHARYNX CARCINOMA; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; RNA TUMOR VIRUS; SOMATIC MUTATION; STOMACH CANCER; T CELL LEUKEMIA; UTERINE CERVIX CANCER; VIRAL GENETICS; VIROLOGY; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS REPLICATION; VIRUS TRANSFORMATION; WART VIRUS; XENOTROPIC MULV RELATED VIRUS;

ANIMALS; CELL TRANSFORMATION, VIRAL; EPIGENOMICS; FORECASTING; HUMANS; NEOPLASMS; ONCOGENIC VIRUSES; RISK FACTORS; RNA, SMALL UNTRANSLATED;

EID: 79960912412     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26087     Document Type: Article

References (119)

1. Williams R,. Remarks on the pathogeny of cancer, with special reference to the microbe theory. Lancet 1891; 138: 606-7.
2. Rous P,. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med 1911; 13: 397-411.
3. Parkin DM,. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-44.
4. Zur Hausen H,. The search for infectious causes of human cancers: where and why. Virology 2009; 392: 1-10.
5. Schiller JT, Lowy DR,. Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol 2010; 64: 23-41.
6. Lipkin WI,. Microbe hunting in the 21st century. Proc Natl Acad Sci USA 2009; 106: 6-7.
7. Gjoerup O, Chang Y,. Update on human polyomaviruses and cancer. Adv Cancer Res 2010; 106: 1-51.
8. Dürst M, Gissmann L, Ikenberg H, zur Hausen H,. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983; 80: 3812-15. (Pubitemid 13063146)
9. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K, Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, DeRisi JL,. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006; 2: e25.
10. Smith RA,. Contamination of clinical specimens with MLV-encoding nucleic acids: implications for XMRV and other candidate human retroviruses. Retrovirology. 2010; 7: 112.
11. Feng H, Shuda M, Chang Y, Moore PS,. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319: 1096-100. (Pubitemid 351300792)
12. Schulz TF,. Cancer and viral infections in immunocompromised individuals. Int J Cancer 2009; 125: 1755-63.
13. Bower M, Palmieri C, Dhillon T,. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006; 19: 14-19. (Pubitemid 43032434)
14. Hofbauer GF, Bavinck JN, Euvrard S,. Organ transplantation and skin cancer: basic problems and new perspectives. Exp Dermatol 2010; 19: 473-82.
15. Jablonska S, Dabrowski J, Jakubowicz K,. Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. Cancer Res 1972; 32: 583-89.
16. Karagas MR, Nelson HH, Sehr P, Waterboer T, Stukel TA, Andrew A, Green AC, Bavinck JN, Perry A, Spencer S, Rees JR, Mott LA, et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 2006; 98: 389-95.
17. Schaper ID, Marcuzzi GP, Weissenborn SJ, Kasper HU, Dries V, Smyth N, Fuchs P, Pfister H,. Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res 2005; 65: 1394-400. (Pubitemid 40270167)
18. von Knebel Doeberitz M, Oltersdorf T, Schwarz E, Gissmann L,. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 1988; 48: 3780-786.
19. zur Hausen H,. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350. (Pubitemid 37328947)
20. Weissenborn SJ, Nindl I, Purdie K, Harwood C, Proby C, Breuer J, Majewski S, Pfister H, Wieland U,. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol 2005; 125: 93-97. (Pubitemid 40981429)
21. Jackson S, Storey A,. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 2000; 19: 592-98. (Pubitemid 30099373)
22. Iftner T, Elbel M, Schopp B, Hiller T, Loizou JI, Caldecott KW, Stubenrauch F,. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J 2002; 21: 4741-48. (Pubitemid 34984361)
23. Hayes RB, Pottern LM, Strickler H, Rabkin C, Pope V, Swanson GM, Greenberg RS, Schoenberg JB, Liff J, Schwartz AG, Hoover RN, Fraumeni JF, Jr. , Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 2000; 82: 718-25. (Pubitemid 30085213)
24. Dennis LK, Dawson DV,. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002; 13: 72-79. (Pubitemid 34031513)
25. Parker AS, Cerhan JR, Lynch CF, Leibovich BC, Cantor KP,. History of urinary tract infection and risk of renal cell carcinoma. Am J Epidemiol 2004; 159: 42-48. (Pubitemid 38049420)
26. Collins D, Hogan AM, Winter DC,. Microbial and viral pathogens in colorectal cancer. Lancet Oncol 2010; 2045: 70186-8.
27. zur Hausen H,. Childhood leukemias and other hematopoietic malignancies: interdependence between an infectious event and chromosomal modifications. Int J Cancer 2008; 125: 1764-70.
28. Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, Chang Y,. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci USA 2008; 105: 16272-77.
29. Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, Moore PS, Becker JC,. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 2010; 84: 7064-72.
30. zur Hausen H,. Proliferation-inducing viruses in non-permissive systems as possible causes of human cancers. Lancet 2001; 357: 381-84. (Pubitemid 32128550)
31. zur Hausen H,. Novel human polyomaviruses-re-emergence of a well known virus family as possible human carcinogens. Int J Cancer 2008; 123: 247-50. (Pubitemid 351842006)
32. Matsuoka M, Jeang KT,. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7: 270-80. (Pubitemid 46480972)
33. McLaughlin-Drubin ME, Munger K,. Viruses associated with human cancer. Biochim Biophys Acta 2008; 1782: 127-50.
34. McGivern DR, Lemon SM,. Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol 2009; 4: 399-415.
35. Ganem D,. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 2010; 120: 939-49.
36. Klein G, Klein E, Kashuba E,. Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes. Biochem Biophys Res Commun 2010; 396: 67-73.
37. Tsai WL, Chung RT,. Viral hepatocarcinogenesis. Oncogene 2010; 29: 2309-24.
38. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM,. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36. (Pubitemid 120035062)
39. Boyer SN, Wazer DE, Band V,. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996; 56: 4620-24. (Pubitemid 26338060)
40. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
41. Klingelhutz AJ, Foster SA, McDougall JK,. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996; 380: 79-82. (Pubitemid 26076241)
42. Duensing S, Münger K,. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004; 109: 157-62. (Pubitemid 38240914)
43. Bornkamm GW,. Epstein-Barr virus and its role in the pathogenesis of Burkitt's lymphoma: an unresolved issue. Sem Cancer Biol 2009; 19: 351-65.
44. Kim C-M, Koike K, Saito I, Miyamura T, Jay G,. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-20. (Pubitemid 21896589)
45. Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH,. The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J 2002; 21: 525-35. (Pubitemid 34174034)
46. Sakamuro D, Furukawa T, Takegami T,. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995; 69: 3893-96.
47. Ray RB, Lagging LM, Meyer K, Ray R,. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 1996; 70: 4438-43. (Pubitemid 26187445)
48. Gale M, Jr, Kwieciszewski B, Dossett M, Nakao H, Katze MG,. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol 1999; 73: 6506-16. (Pubitemid 29327831)
49. Park JS, Yang JM, Min MK,. Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. Biochem Biophys Res Commun 2000; 267: 581-87. (Pubitemid 30076841)
50. Park SZ, Nagorney DM, Czaja AJ,. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000; 45: 1944-48.
51. Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, Kanzler S,. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol 2009; 15: 578-82.
52. Goodwin EC, DiMaio D,. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci USA 2000; 97: 12513-18.
53. Wells SI, Aronow BJ, Wise TM, Williams SS, Couget JA, Howley PM,. Transcriptome signature of irreversible senescence in human papillomavirus- positive cervical cancer cells. Proc Natl Acad Sci USA 2003; 100: 7093-98. (Pubitemid 36706398)
54. Thierry F, Benotmane MA, Demeret C, Mori M, Teissier S, Desaintes C,. A genomic approach reveals a novel mitotic pathway in papillomavirus carcinogenesis. Cancer Res 2004; 64: 895-903. (Pubitemid 38176890)
55. Kelley ML, Keiger KE, Lee CJ, Huibregtse JM,. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J Virol 2005; 79: 3737-47. (Pubitemid 40327961)
56. Kuner R, Vogt M, Sultmann H, Buness A, Dymalla S, Bulkescher J, Fellmann M, Butz K, Poustka A, Hoppe-Seyler F,. Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses. J Mol Med 2007; 85: 1253-62. (Pubitemid 47622224)
57. Holland D, Hoppe-Seyler K, Schuller B, Lohrey C, Maroldt J, Dürst M, Hoppe-Seyler F,. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Cancer Res 2008; 68: 9964-72.
58. Simon JA, Lange CA,. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647: 21-29.
59. Tiemann K, Rossi JJ,. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 2009; 1: 142-51.
60. Guo H, Ingolia NT, Weissman JS, Bartel DP,. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-40.
61. Garzon R, Calin GA, Croce CM,. MicroRNAs in cancer. Annu Rev Med 2009; 60: 167-79.
62. Umbach JL, Cullen BR,. The role of RNAi and microRNAs in animal virus replication and antiviral immunity. Genes Dev 2009; 23: 1151-64.
63. Sullivan CS, Grundhoff AT, Tevethia S, Pipas JM, Ganem D,. SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells. Nature 2005; 435: 682-86. (Pubitemid 40825513)
64. Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O,. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 2009; 5: 376-85.
65. Choy EY, Siu KL, Kok KH, Lung RW, Tsang CM, To KF, Kwong DL, Tsao SW, Jin DY,. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med 2008; 205: 2551-60.
66. Ziegelbauer JM, Sullivan CS, Ganem D,. Tandem array-based expression screens identify host mRNA targets of virus-encoded microRNAs. Nat Genet 2009; 41: 130-34.
67. Meckes DG, Jr, Shair KH, Marquitz AR, Kung CP, Edwards RH, Raab-Traub N,. Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci USA 2010; 107: 20370-75.
68. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, de Gruijl TD, Würdinger T, Middeldorp JM,. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 2010; 107: 6328-33.
69. O'Hara AJ, Wang L, Dezube BJ, Harrington WJ, Jr, Damania B, Dittmer DP,. Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma. Blood 2009; 113: 5938-41.
70. Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA, Cullen BR,. Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol 2010; 84: 11670-78.
71. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA,. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008; 27: 2575-82. (Pubitemid 351550884)
72. Pichler K, Schneider G, Grassmann R,. MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-transformed T lymphocytes. Retrovirology 2008; 5: 100.
73. Wang X, Wang HK, McCoy JP, Banerjee NS, Rader JS, Broker TR, Meyers C, Chow LT, Zheng ZM,. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 2009; 15: 637-47.
74. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S,. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009; 49: 1098-112.
75. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P,. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-81. (Pubitemid 41266486)
76. Lu S, Cullen BR,. Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J Virol 2004; 78: 12868-76. (Pubitemid 39507795)
77. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP,. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010; 465: 1033-38.
78. Kim TK, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, Harmin DA, Laptewicz M, Barbara-Haley K, Kuersten S, Markenscoff-Papadimitriou E, Kuhl D, et al. Widespread transcription at neuronal activity-regulated enhancers. Nature 2010; 465: 182-87.
79. Ørom UA, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G, Lai F, Zytnicki M, Notredame C, Huang Q, Guigo R, Shiekhattar R,. Long noncoding RNAs with enhancer-like function in human cells. Cell 2010; 143: 46-58.
80. Sharma S, Kelly TK, Jones PA,. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36.
81. Ferrari R, Berk AJ, Kurdistani SK,. Viral manipulation of the host epigenome for oncogenic transformation. Nat Rev Genet 2009; 10: 290-94.
82. Fernandez AF, Esteller M,. Viral epigenomes in human tumorigenesis. Oncogene 2010; 29: 1405-20.
83. Jung JK, Arora P, Pagano JS, Jang KL,. Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res 2007; 67: 5771-78. (Pubitemid 46985010)
84. Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, Morikawa T, Nakaya T, Sakatani T, Takada K, Fukayama M,. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 2009; 69: 2766-74.
85. Laurson J, Khan S, Chung R, Cross K, Raj K,. Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 2010; 31: 918-26.
86. Rincon-Orozco B, Halec G, Rosenberger S, Muschik D, Nindl I, Bachmann A, Ritter TM, Dondog B, Ly R, Bosch FX, Zawatzky R, Rösl F,. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res 2009; 69: 8718-25.
87. Kelly TK, Carvalho DD, Jones PA,. Epigenetic modifications as therapeutic targets. Nat Biotech 2010; 28: 1069-78.
88. Mercader M, Taddeo B, Panella JR, Chandran B, Nickoloff BJ, Foreman KE,. Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am J Pathol 2000; 156: 1961-71. (Pubitemid 30641765)
89. Varthakavi V, Smith RM, Deng H, Sun R, Spearman P,. Human immunodeficiency virus type-1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus through induction of KSHV Rta. Virology 2002; 297: 270-80. (Pubitemid 34734899)
90. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F,. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990; 345: 84-86.
91. Barillari G, Gendelman R, Gallo RC, Ensoli B,. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 1993; 90: 7941-45. (Pubitemid 23260830)
92. Chin-Hong PV, Husnik M, Cranston RD, Colfax G, Buchbinder S, Da Costa M, Darragh T, Jones D, Judson F, Koblin B, Mayer KH, Palefsky JM,. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS 2009; 23: 1135-42.
93. Smith-McCune KK, Shiboski S, Chirenje MZ, Magure T, Tuveson J, Ma Y, Da Costa M, Moscicki AB, Palefsky JM, Makunike-Mutasa R, Chipato T, van der Straten A, et al. Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One 2010; 5: e10094.
94. Kew MC,. Interaction between hepatitis B and C viruses in hepatocellular carcinogenesis. J Viral Hepat 2006; 13: 145-49.
95. Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, Oh JK, Park S, Kim YJ, Shin HR, Yoo KY, Park SK,. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer 2011; 128: 176-84.
96. Wedemeyer H, Manns MP,. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroent Hepatol 2010; 7: 31-38.
97. Schlehofer JR, Ehrbar M, zur Hausen H,. Vaccinia virus, herpes simplex virus, and carcinogens induce DNA amplification in a human cell line and support replication of a helpervirus dependent parvovirus. Virology 1986; 152: 110-17. (Pubitemid 16065534)
98. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR,. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307: 178-80. (Pubitemid 14132908)
99. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS,; Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-55.
100. Lowy DR, Schiller JT,. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116: 1167-73.
101. Paavonen J, Naud P, Salmerõn J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14.
102. FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341: c3493. doi: 10.1136/bmj.c3493.
103. Parkin DM, Bray F,. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24 (Suppl 3): 11-25.
104. Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF,. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 2010; 8: 333-45.
105. Delecluse HJ, Feederle R, Behrends U, Mautner J,. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus. Semin Cancer Biol 2008; 18: 409-15.
106. Kanodia S, Da Silva DM, Kast WM,. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 2008; 122: 247-59. (Pubitemid 350234709)
107. Gissmann L, Nieto K,. The therapeutic vaccine: is it feasible? Arch Med Res 2009; 40: 493-98.
108. Trimble CL, Frazer IH,. Development of therapeutic HPV vaccines. Lancet Oncol 2009; 10: 975-80.
109. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, et al. Vaccination against HPV-16 oncoproteins for vulval intraepithelial neoplasia. New Engl J Med 2009; 361: 1838-47.
110. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F,. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 2000; 97: 6693-97. (Pubitemid 30412776)
111. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F,. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003; 22: 5938-45. (Pubitemid 37175872)
112. DeFilippis RA, Goodwin EC, Wu L, DiMaio D,. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 2003; 77: 1551-63. (Pubitemid 36055574)
113. Griffin H, Elston R, Jackson D, Ansell K, Coleman M, Winter G, Doorbar J,. Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J Mol Biol 2006; 355: 360-78. (Pubitemid 41785744)
114. Lagrange M, Boulade-Ladame C, Mailly L, Weiss E, Orfanoudakis G, Deryckere F,. Intracellular scFvs against the viral E6 oncoprotein provoke apoptosis in human papillomavirus-positive cancer cells. Biochem Biophys Res Comm 2007; 361: 487-92. (Pubitemid 47187284)
115. Dymalla S, Scheffner M, Weber E, Sehr P, Lohrey C, Hoppe-Seyler F, Hoppe-Seyler K,. A novel peptide motif binding to and blocking the intracellular activity of the human papillomavirus E6 oncoprotein. J Mol Med 2009; 87: 321-31.
116. Wells SI, Francis DA, Karpova AY, Dowhanick JJ, Benson JD, Howley PM,. Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)-dependent pathways. EMBO J 2000; 19: 5762-71.
117. Hall AH, Alexander KA,. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol 2003; 77: 6066-69. (Pubitemid 36538997)
118. Leader B, Baca QJ, Golan DE,. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008; 7: 21-39.
119. Bardou C, Borie C, Bickle M, Rudkin BB, Colas P,. Peptide aptamers for small molecule drug discovery. Methods Mol Biol 2009; 535: 373-88.